Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TJYIW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BMS-986497
|
|||||
| Synonyms |
ORM-6151; BMS-986497
Click to Show/Hide
|
|||||
| Organization |
Orum Therapeutics (Originator) (No Rights);Bristol-Myers Squibb (Top20 MNC)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
OR000283
|
Antibody Info | ||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
SMol006
|
Payload Info | ||||
| Therapeutic Target |
CRBN×GSPT1
|
Target Info | ||||
| Linker Name |
β-glucuronide linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Acute myeloid leukaemia |
1 Trials
|
||||||||
| Myelodysplastic syndrome |
1 Trials
|